SCHEMBL5648976

SCHEMBL5648976

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cccc(O)c3[nH]2)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.49
WDR77 Q9BQA1 1/20 0.49
HTT P42858 2/20 0.45
TMEM97 Q5BJF2 2/20 0.45
SIGMAR1 Q99720 2/20 0.45
APP P05067 3/20 0.44
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.42
ROCK1 Q13464 3/20 0.41
ROCK2 O75116 2/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
OPRM1 P35372 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CHEK1 O14757 1/20 0.40
DAPK3 O43293 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PAK4 O96013 1/20 0.40
ABL1 P00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649700 0.92 PRMT5 (0.42) PRMT5WDR77HTTTMEM97SIGMAR1
SCHEMBL5651909 0.89 TP53 (0.45) PRMT5WDR77HTTAPPGAA
SCHEMBL5651321 0.88 FLT3 (0.46) ROCK1ROCK2HDAC6LRRK2
SCHEMBL5648995 0.86 PRMT5 (0.49) PRMT5WDR77HTTTMEM97SIGMAR1
SCHEMBL5654556 0.84 PRMT5 (0.42) PRMT5WDR77HTTGAAKMT2A
SCHEMBL5647859 0.84 HDAC6 (0.46) HTTGAAKMT2ATP53SMN1; SMN2
SCHEMBL5653023 0.83 PRMT5 (0.50) PRMT5WDR77HTTTMEM97SIGMAR1
SCHEMBL5653197 0.83 PRMT5 (0.48) PRMT5WDR77HTTTMEM97SIGMAR1
SCHEMBL5650247 0.82 PRSS12 (0.50) PRMT5WDR77HTTTMEM97SIGMAR1
SCHEMBL5651233 0.82 FLT3 (0.54) PRMT5WDR77HTTTMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PRMT5 448/4885WDR77 1101/4885HTT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.